PR Newswire All News ReleasesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 07:10:00·⟳ 抓取 07:10:18 +18s·⚡ 决策 08-29 07:11:47 +1m29s·59.4 天前
KTMC对EyePoint投资者损失启动调查，核心事实仍是8月17日DURAVYU三期LUGANO未达主要终点
本条是律所投资者调查广告，重复引用已在8月17日公开并造成EYPT大幅下跌的LUGANO三期未达主要终点事件，没有新增诉讼立案、处罚、公司确认/否认或量化赔偿风险，因此不构成新的做空或做多催化。
📄 原文PR Newswire All News Releases↗ 原文
RADNOR, Pa., Aug. 28, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized s…
不做 EyePoint, Inc.（EYPT.US）
不做：KTMC调查通知只是重复8月17日已公开且已大幅定价的临床失败事实，未新增正式诉讼、监管动作、赔偿量级或公司基本面变化，边际做空催化不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
PRNewswire本条来自KTMC，实质是证券律所基于EyePoint此前DURAVYU湿性AMD三期LUGANO主要终点未达而招揽投资者；EyePoint原始8-K/新闻稿已在2026-08-17披露该临床结果，市场当日已出现约三分之二跌幅，多家律所也已在8月26日至27日发布类似调查通知。当前信息没有改变药物监管路径、收入预期或法律责任的可量化状态，做空边际催化不足，做多也没有反转事实。
消息传播链
- EyePoint披露DURAVYU三期LUGANO在全数据集未达到BCVA主要终点，同时称剔除4%不对称队列后的事后分析显示非劣效。市场反应:EYPT当日被多家媒体记录为下跌约66%至69%。
- 媒体报道EYPT因DURAVYU三期未达主要终点盘中大跌约69%，显示原催化已即时进入市场定价。市场反应:报道时称股价约4.585美元，较前收14.75美元下跌68.92%。
- 另一家律所已在8月26日发布同类证券调查通知，说明律所招揽类消息不是本条新增事实。
- Pomerantz同样就8月17日LUGANO失败事实发布投资者调查，进一步证明本条KTMC通知没有独占新增信息。
- KTMC发布投资者调查广告，核心仍是8月17日已披露临床失败和股价下跌。市场反应:发布时间为美股周五盘后，不构成新的可成交盘中价格发现。
主要风险
- 若后续出现正式集体诉讼、监管调查或公司披露新的LUCIA失败数据，才可能形成新的公司级负面催化。
- DURAVYU仍有第二项LUCIA三期数据预计2026年四季度公布，未来二次数据会重新决定临床资产价值。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-17 · 影响 weakens
原始临床失败已在8月17日公开并造成约三分之二跌幅，8月28日KTMC通知缺少新的强空事实。
检索:EyePoint LUGANO DURAVYU August 17 2026 stock dropped 66 law firm investigation 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-17 · 影响 none
公司称事后剔除4%不对称队列后显示非劣效且LUCIA数据预计四季度公布，但这不是8月28日律师广告带来的新增反转催化。
检索:EyePoint LUGANO ad hoc analysis LUCIA Q4 2026 NDA H1 2027 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足不影响结论；当前可核验事实已经足以判断为无新增催化而回避。
方向:律所调查广告通常不是新的基本面事件；本次核心负面催化已在8月17日落地并被大幅定价。
涨幅量级:未使用外部价格先例校准幅度，因为本条不是新的临床结果或正式诉讼事件。
形态:同类律所调查通知更多反映既有跌幅后的法律招揽，缺少独立方向性。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,984 字
RADNOR, Pa., Aug. 28, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
EyePoint Reports Disappointing Phase 3 Clinical Trials
On August 17, 2026, EyePoint issued a press release "announc[ing] topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD)." Specifically, EyePoint disclosed that DURAVYU did not meet the prespecified primary endpoint -- change in best-corrected visual acuity versus on-label aflibercept -- in the full dataset of the company's Phase 3 LUGANO trial in wet age-related macular degeneration.
EyePoint's Stock Drops Over 66%
Following the news of EyePoint, Inc.'s poor clinical trial results, the company's stock price fell over 66%.
Investors who purchased EyePoint, Inc. (NASDAQ: EYPT) securities and experienced losses may have legal rights under the federal securities laws.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired EyePoint, Inc. securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/meypt-eyepoint-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=eypt&mktm=PR
There is no cost or obligation to speak with an attorney.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.
CONTACT:
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
SOURCE Kessler Topaz Meltzer & Check, LLP
EyePoint Reports Disappointing Phase 3 Clinical Trials
On August 17, 2026, EyePoint issued a press release "announc[ing] topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD)." Specifically, EyePoint disclosed that DURAVYU did not meet the prespecified primary endpoint -- change in best-corrected visual acuity versus on-label aflibercept -- in the full dataset of the company's Phase 3 LUGANO trial in wet age-related macular degeneration.
EyePoint's Stock Drops Over 66%
Following the news of EyePoint, Inc.'s poor clinical trial results, the company's stock price fell over 66%.
Investors who purchased EyePoint, Inc. (NASDAQ: EYPT) securities and experienced losses may have legal rights under the federal securities laws.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired EyePoint, Inc. securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/meypt-eyepoint-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=eypt&mktm=PR
There is no cost or obligation to speak with an attorney.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.
CONTACT:
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
SOURCE Kessler Topaz Meltzer & Check, LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。